Haleon plc
NYSE•HLN
CEO: Mr. Brian James McNamara
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
連絡先情報
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
時価総額
$43.05B
PER (TTM)
30.8
35.6
配当利回り
2.0%
52週高値
$11.42
52週安値
$8.71
52週レンジ
順位34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
堅調 • 4.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q4 2025 データ
売上高
$7.39B+0.00%
直近4四半期の推移
EPS
$0.25+0.00%
直近4四半期の推移
フリーCF
$1.68B+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Operating Profit Rises Strongly Operating profit £2.4B, achieving 9.3% growth; Organic operating profit margin reached 10.5% versus 5.0% prior year.
Revenue Declines Slightly Revenue £11.0B, down 1.8% compared to 2024; Basic EPS grew to 18.6p from 15.8p previously reported.
Strong Cash Flow Generation Net cash inflow from operating activities £2.6B; Total borrowings net debt leverage remains stable at 2.6x Adjusted EBITDA.
リスク要因
Intense Market Competition Risks Private label growth and consumer preference shifts threaten market share; execution failure risks brand loyalty erosion.
Geopolitical Supply Chain Volatility Geopolitical instability, trade barriers, and inflation increase input costs and disrupt global supply chain operations.
Cyber Security Threat Escalation Increased cyber-attacks risk operational disruption; investment in security culture and technology remains critical focus area.
見通し
Executing Win As One Strategy Focus remains on delivering growth, productivity, and culture agenda; new operating model expected to yield £175M-£200M savings.
ESG Targets Progress Focus Aiming for 55% Scope 1 and 2 carbon reduction by 2030; committed to reducing virgin plastic use by 50% by 2030.
Shareholder Return Commitment Board proposed 4.9p final dividend; continuation of share buyback programme planned for 2026.
同業比較
売上高 (TTM)
$244.49B
$129.66B
$30.01B
粗利益率 (最新四半期)
82.5%
78.3%
68.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TAK | $56.39B | 79.2 | 1.6% | 31.5% |
| BDX | $56.34B | 25.2 | 6.9% | 35.6% |
| ZTS | $50.98B | 19.8 | 58.2% | 61.4% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.3%
緩やかな成長
4四半期純利益CAGR
7.7%
収益性の着実な向上
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月29日
EPS:$0.25
|売上高:$7.57B
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし